Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with C3G every year
Source: pmlive.com
David Kavanagh News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Kavanagh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Kavanagh Today - Breaking & Trending Today
Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
Source: hcplive.com
David Kavanagh, MBChB, PhD: Iptacopan Offers Hope for C3 Glomerulopathy
A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.
Source: hcplive.com
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Source: prnewswire.com
Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Source: finanznachrichten.de